JOSÉ LUIS
REVUELTA HERRERO
Profesor asociado de Ciencias de la Salud
Instituto de Investigación Sanitaria Gregorio Marañón
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Instituto de Investigación Sanitaria Gregorio Marañón (17)
2023
-
Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 2855-2882
-
Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy
Frontiers in Oncology, Vol. 13
2022
-
A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application
Frontiers in Oncology, Vol. 12
-
A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital
Frontiers in Public Health, Vol. 10
-
Medication guide for the perioperative management of oral antineoplastic agents in cancer patients
Expert Opinion on Drug Safety, Vol. 21, Núm. 1, pp. 107-119
-
Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients
Journal of Oncology Pharmacy Practice, Vol. 28, Núm. 5, pp. 1259-1263
-
Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App
Frontiers in Oncology, Vol. 12
2021
-
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice
Supportive Care in Cancer, Vol. 29, Núm. 8, pp. 4673-4681
-
Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective
Frontiers in Oncology, Vol. 11
-
Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain
Expert Review of Clinical Pharmacology, Vol. 14, Núm. 2, pp. 249-260
-
Dpyd exome, mrna expression and uracil levels in early severe toxicity to fluoropyrimidines: An extreme phenotype approach
Journal of Personalized Medicine, Vol. 11, Núm. 8
-
Tocilizumab as salvage treatment of refractory pulmonary acute graft-versus-host disease
Journal of Oncology Pharmacy Practice, Vol. 27, Núm. 3, pp. 751-755
2019
-
Drug safety surveillance within a strategy for the management of non-chemotherapy drug-induced neutropenia
International Journal of Clinical Pharmacy, Vol. 41, Núm. 5, pp. 1143-1147
-
Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice
Expert Opinion on Drug Safety, Vol. 18, Núm. 9, pp. 861-868
2018
-
Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice
Journal of Clinical Pharmacy and Therapeutics, Vol. 43, Núm. 6, pp. 906-909
-
Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients
Annals of Pharmacotherapy, Vol. 52, Núm. 1, pp. 11-18
-
Pazopanib-Associated Transient Ischemic Attack
American journal of therapeutics, Vol. 25, Núm. 3, pp. e393-e394